189 related articles for article (PubMed ID: 29455269)
1. The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials.
Zhao TT; Xu H; Xu HM; Wang ZN; Xu YY; Song YX; Yin SC; Liu XY; Miao ZF
Gastric Cancer; 2018 May; 21(3):361-371. PubMed ID: 29455269
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis.
Park S; Nam CM; Kim SG; Mun JE; Rha SY; Chung HC
Eur J Cancer; 2021 Feb; 144():49-60. PubMed ID: 33338727
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis.
Gong H; Su Y; Zhao L; Ma L; Zhang L; Hou L; Li T; Niu S; Zhang H; Li C; Jin X; Ge L; Leng G; Liu Y
J Clin Pharm Ther; 2022 Apr; 47(4):493-506. PubMed ID: 34796971
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Low-Dose Apatinib Combined with Chemotherapy as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis.
Wang L; Li J; Chen H
Chemotherapy; 2024; 69(1):11-22. PubMed ID: 37339610
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness of neoadjuvant chemotherapy in advanced gastric cancer: an updated meta-analysis of randomized controlled trials.
Xiong B; Ma L; Cheng Y; Zhang C
Eur J Surg Oncol; 2014 Oct; 40(10):1321-30. PubMed ID: 25239442
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis.
Ren Z; Sun J; Sun X; Hou H; Li K; Ge Q
Oncotarget; 2017 Jul; 8(29):48253-48262. PubMed ID: 28477027
[TBL] [Abstract][Full Text] [Related]
7. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
[TBL] [Abstract][Full Text] [Related]
8. The role of targeted agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials.
Wang CW; Fang XH
Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1725-32. PubMed ID: 27212163
[TBL] [Abstract][Full Text] [Related]
9. Doublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled Trials.
Zhang Y; Ma B; Huang XT; Li YS; Wang Y; Liu ZL
Medicine (Baltimore); 2016 Feb; 95(8):e2792. PubMed ID: 26937908
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials.
Huang J; Zhao Y; Xu Y; Zhu Y; Huang J; Liu Y; Zhao L; Li Z; Liu H; Wang QL; Qi X
Oncotarget; 2016 Jun; 7(23):34824-31. PubMed ID: 27166187
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis.
Huang M; Li J; Yu X; Xu Q; Zhang X; Dai X; Li S; Sheng L; Huang K; Liu L
Front Oncol; 2021; 11():734323. PubMed ID: 34745955
[TBL] [Abstract][Full Text] [Related]
12. The efficiency and safety of trastuzumab for advanced gastric and gastroesophageal cancer: a meta-analysis of five randomized controlled trials.
Xiong B; Ma L; Huang W; Luo H; Zeng Y; Tian Y
Growth Factors; 2016 Dec; 34(5-6):187-195. PubMed ID: 27921577
[TBL] [Abstract][Full Text] [Related]
13. The relative efficacy and safety of targeted agents used in combination with chemotherapy in treating patients with untreated advanced gastric cancer: a network meta-analysis.
Xie S; Zhang H; Wang X; Ge Q; Hu J
Oncotarget; 2017 Apr; 8(16):26959-26968. PubMed ID: 28460479
[TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis.
Zhu L; Liu J; Ma S
Pathol Oncol Res; 2016 Oct; 22(4):853-61. PubMed ID: 27236591
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.
Wang Y; Zhang H; Shen W; He P; Zhou Z
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1751-1768. PubMed ID: 29797220
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?
Pasini F; Fraccon AP; Modena Y; Bencivenga M; Giacopuzzi S; La Russa F; Gusella M; de Manzoni G
Gastric Cancer; 2017 Jan; 20(1):31-42. PubMed ID: 27568322
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer.
Chen HD; Zhou J; Wen F; Zhang PF; Zhou KX; Zheng HR; Yang Y; Li Q
J Cancer Res Clin Oncol; 2017 Feb; 143(2):361-368. PubMed ID: 27798730
[TBL] [Abstract][Full Text] [Related]
18. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
19. The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials.
Qi WX; Shen Z; Tang LN; Yao Y
Tumour Biol; 2014 Aug; 35(8):7675-83. PubMed ID: 24801910
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Molecular Targeted Agents Plus Chemotherapy for Second-Line Therapy of Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Trials.
Pei X; Liu Y; Sun L; Zhang J; Fang Y; Liao X; Liu J; Zhang C; Yin T
Clin Colorectal Cancer; 2016 Dec; 15(4):e149-e156. PubMed ID: 27155750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
